Asia Pacific Stem Cell Market

APAC Stem Cell Market Size (2022 to 2027)

The size of the Asia Pacific Stem Cell Market is forecasted to grow USD 3641.00 million in 2022. It is estimated to reach USD 5863.87 million by the end of 2027, with a CAGR of 10%, during the forecast period.

The growth of the market is mainly driven due to better regulatory support through encouraging government policies and increasing awareness among the public. In addition, the Asia-pacific stem cell market is invested in various research organizations and developments of the stem cell industry. Innovation and implementation of multiple technologies and increasing population continuously in this region enhance the market's demand.

The stem cell market expansion in the APAC region is further driven by improved regulatory support, including promoting government initiatives and raising public awareness. Furthermore, the Asia Pacific stem cell market invests in various stem cell research organizations and innovations. As a result, the market demand is being boosted by innovation and the adoption of numerous technologies, and an ever-increasing population in this area.

The increased quality of differentiated cells resulting from efficient manufacturing as a result of partnerships is anticipated to expand the stem cell market's potential possibilities. Furthermore, during the projection period, the market would benefit from integrating several sectors such as materials, devices, chemical compounds, and biologics. In addition, favorable regulatory frameworks in emerging regions are projected to create substantial development possibilities for domestic and foreign companies in the stem cell manufacturing industry.

The cost of storing and maintaining stem cells is considerably higher, one of the most significant constraints in the stem cell industry. The research requires a significant amount of cash, and even a minor mistake in the research can be quite costly. In addition, it needs a highly qualified staff, which is extremely difficult to come by in today's market. Furthermore, the debate over research ethics and the complexity of the stem cell technique impacts market growth.

This research report on the APAC Stem Cell Market has been segmented and sub-segmented the Europe Stem Cell Market into the following categories:

By Treatment mode: 

• Allogeneic
• Autologous

By Cells Type: 

• Adult Stem Cells
• Induced Pluripotent Stem Cells
• Human Embryonic Stem Cells
• Others

By Technology: 

• Cell Acquisition
• Cell Production
• Cryopreservation
• Others

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, the APAC stem cell market is one of the fastest-growing regional markets in the global market. It is predicted to account for a substantial share in the global market during the forecast period. The stem cell market of India is anticipated to grow at the compound annual growth rate in upcoming years due to high awareness about stem cells, developments in tissue engineering, and increasing patients of chronic and genetic disorders. Also, the market has a substantial segment of pluripotent and embryonic products. Hence the market is growing this year. In addition, several companies are trying to develop new products in the market.

The Chinese stem cell market has the most significant growth in the Asia-pacific region. The presence of various diseases such as kidney, cardiac, hematological, diabetes mellitus, and osteoarthritis boosts the market's demand. Also, rapid development in stem cell therapy and its awareness is fuelling the Chinese market growth. China has applied for more stem cell patents for developments and continuous investment in the research and development of stem cells. The majority of key players are in China that accounted for the highest share of the stem cell market.

The stem cell market of Japan has projected to grow due to most of the prominent key players focuses on the development of gene therapy. Also, the Japanese health ministry approved fast-track stem cell therapy (Sterimac), and this treatment is available to Japanese people.

KEY MARKET PLAYERS:

Some of the Promising Companies Operating the Asia Pacific Stem Cell Market Profiled in the Report are Athersys, StemCells Inc, Cryo-Cell International, Geron Corporation, Mesoblast Ltd, Aastrom Biosciences Inc, Celgene Corporation, Invitrogen and Cytori Therapeutics Inc.